Price Change for HEPLISAV-B, Hepatitis B Vaccine (Recombinant) – 2/23/23

[et_pb_section fb_built=”1″ theme_builder_area=”post_content” _builder_version=”4.19.4″ _module_preset=”default”][et_pb_row _builder_version=”4.19.4″ _module_preset=”default” theme_builder_area=”post_content”][et_pb_column _builder_version=”4.19.4″ _module_preset=”default” type=”4_4″ theme_builder_area=”post_content”][et_pb_code _builder_version=”4.19.4″ _module_preset=”default” theme_builder_area=”post_content” hover_enabled=”0″ sticky_enabled=”0″] /* OUTLOOK-SPECIFIC STYLES */ li { text-indent: -1em; padding: 0; margin: 0; /* line-height: 1.2; Remove after testing */ } ul, ol { padding: 0; margin: 0 0 0 40px; } p { margin: 0; padding: 0; margin-bottom: 0; } Announcing a price change for HEPLISAV-B®, {Hepatitis B Vaccine (Recombinant), Adjuvanted}

This message is being sent by www.BuyandBill.com on behalf of Dynavax Technologies

HeplisavB-logo_Reg-01 _002_ _002_.png

Effective March 1, 2023 the pricing of HEPLISAV-B® will change as outlined below.

 

Please take a moment to update any of your reimbursement, billing, and ordering systems to reflect this change. 

HEPLISAV-B® NDC Code and Pricing:

CPT

Code

11 Digit NDC Code

Effective

Date

Product

Description

WAC Per

Package

WAC Per

Syringe

Estimated AWP per Package

Estimated

AWP per syringe

90739

43528-0003-05

3/1/2023

Carton of five 0.5 mL Syringes

$703.00

$140.60

$843.60

$168.72

HEPLISAV-B® NDC Code and Pricing Including CDC Federal Excise Tax ($.75 per dose)

CPT

Code

11 Digit NDC Code

Effective

Date

Product

Description

WAC Per

Package

WAC Per

Syringe

Estimated AWP per Package

Estimated

AWP per syringe

90739

43528-0003-05

3/1/2022

Carton of five 0.5 mL Syringes

$706.75

$141.35

$847.35

$169.47

Dynavax is notifying all customers and business associates about this change, and we would appreciate your partnership in helping us ensure that all systems and locations involved with HEPLISAV-B are updated with the new HEPLISAV-B pricing.

 

For any questions, contact DYNAVAX at 1-84-HEPLISAV (1-844-375-4728)

 

INDICATION

HEPLISAV-B is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older.

 

IMPORTANT SAFETY INFORMATION

Do not administer HEPLISAV-B to individuals with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any hepatitis B vaccine or to any component of HEPLISAV-B, including yeast.

 

Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of HEPLISAV-B.

 

Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to HEPLISAV-B.

 

Hepatitis B has a long incubation period. HEPLISAV-B may not prevent hepatitis B infection in individuals who have an unrecognized hepatitis B infection at the time of vaccine administration.

 

The most common patient-reported adverse reactions reported within 7 days of vaccination were injection site pain (23%-39%), fatigue (11%-17%), and headache (8%-17%).



Please see full Prescribing Information.

 

US-23-00-00017

 

Dynavax | 2100 Powell Street Suite 900 | Emeryville, CA 94608

 

www.dynavax.com  www.heplisavb.com


DynavaxLogo3.10.png